Shots:
- The US FDA has approved ProVee System for the treatment of benign prostatic hyperplasia (BPH)
- Approval was backed by the ProVIDE study assessing ProVee in men, which met its 1 & 2EPs, showing significant & durable symptom relief as well as improved urinary flow through 12mos. compared to sham, with preserved sexual function & no post-procedure catheterization; results were published in The Journal of Urology
- ProVee, a prostatic urethral stent, gently opens the obstructed prostate to relieve BPH-related lower urinary tract symptoms without cutting, burning, tearing, or piercing prostatic tissue, offering improved safety profile & faster recovery
Ref: PRnewswire | Image: ProVerum |Press Release
Related News: Francis Medical’s Vanquish Water Vapor System Receives the US FDA 510(k) Clearance for Prostate Tissue Ablation
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
